DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Cancer Vaccines Market

Global Cancer Vaccines Market Opportunities and Forecast 2020-2027

  • DLR2478
  • 02 August, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Cancer Vaccines Market, By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Indication (Cervical Cancer, Prostate Cancer, Others), By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By End-User (Adults, Children), and opportunities and forecast 2020-2027

Cancer Vaccines Market Overview

Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of the body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. The increasing number of cancer patients across the world is the key factor to boost the growth of the global Cancer Vaccines market.  According to National Cancer Institute, Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million.

Moreover, other factors which are reasonable to fuel the growth of the global Cancer Vaccines market are the rising old age population, surge in patient awareness towards cancer therapy, and increase in cancer vaccines usage combined with other therapies. Additionally, an increase in investments and government funding in the development of cancer vaccines by manufacturers are the major factors that drive the growth of the Cancer Vaccines market. As well, technological developments in cancer vaccines, the launch of novel cancer vaccines, rise in health care services, and expenditure further remarkably contribute to the Cancer Vaccines market’s expansion.

On the other hand, the high cost for developing cancer vaccines and the longer period required for manufacturing a single vaccine are anticipated to hamper the growth of the market.

Covid-19 Impact on Cancer Vaccines Market

In addition, the current Cancer Vaccines Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Vaccines Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Cancer Vaccines Market Segment Overview

Based on technology, the recombinant cancer vaccines segment has the largest share of the market and is projected to maintain its supremacy over the forecast period. An increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in the number of approved cancer vaccines developed using recombinant technology are the crucial factors that boost the growth of this segment. Additionally, by indication, the Cervical Cancer segment has the maximum share of the global cancer vaccines market.  This is due to the high prevalence of cervical cancer and the increase in the number of people suffering from human papilloma virus (HPV) infections. In addition, drug development in the field of cervical cancer, and an increase in patient awareness toward cervical cancer propel the growth of this segment.  

Cancer Vaccines Market, By Technology

·       Dendritic Cells (DC) Cancer Vaccines
·       Recombinant Cancer Vaccines
·       Antigen/Adjuvant Cancer Vaccines
·       Viral Vector & DNA Cancer Vaccines

Cancer Vaccines Market, By Indication

·       Cervical Cancer
·       Prostate Cancer
·       Others

Cancer Vaccines Market, By Type

·       Preventive Cancer Vaccines
·       Therapeutic Cancer Vaccines

Cancer Vaccines Market, By End-User

·       Adults
·       Children

Cancer Vaccines Market Regional Overview

Region-wise, North America dominates the Cancer Vaccines market owing to a major market share of the U.S. Similarly, Asia Pacific is expected to expand with an impressive CAGR over the forecast period.  This is mainly due to rising government initiatives, increased focus of players on the vaccine technology market in India, and rising immunization initiatives by the World Health Organization and GAVI. In addition to this, rising adoption of cancer vaccines, an increasing number of cancer patients in developing countries, rising healthcare reforms, and technological advancements in cancer vaccines are other factors that majorly contribute to the growth of the Cancer Vaccines market in this region.

Cancer Vaccines Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Cancer Vaccines Market Competitor overview

Some key developments and strategies adopted by manufacturers in Cancer Vaccines are highlighted below.

·       In July 2021, Using nanotechnology, a team of researchers in China have designed personalised tumour vaccines based on bacterial cytoplasmic membranes and cell membranes from resected tumour tissue. These scientists said that these vaccines could potentially offer an opportunity for the development of individualised cancer vaccines to fight against a broad range of tumours.

Cancer Vaccines Market, Key Players

·       AstraZeneca plc
·       Prima Sanofi
·       BioMed
·       GlaxoSmithKline
·       Merck
·       Aduro BioTech
·       OncoThyreon
·       Oxford BioMedica
·       Advaxis Inc.
·       Amgen Inc.
·       Dynavax Technologies Corporation
·       Generex Biotechnology Corporation
·       Immunocellular Therapeutics, Ltd
·       Sanpower Group Co. Ltd.
·       UbiVac 
·       Vaccinogen, Inc.

Cancer Vaccines Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Technology
        • 5.2.1. Dendritic Cells (DC) Cancer Vaccines
        • 5.2.2. Recombinant Cancer Vaccines
        • 5.2.3. Antigen/Adjuvant Cancer Vaccines
        • 5.2.4. Viral Vector & DNA Cancer Vaccines
      • 5.3. Market Analysis, Insights and Forecast – By Indication
        • 5.3.1. Cervical Cancer
        • 5.3.2. Prostate Cancer
        • 5.3.3. Others
      • 5.4. Market Analysis, Insights and Forecast – By Type
        • 5.4.1. Preventive Cancer Vaccines
        • 5.4.2. Therapeutic Cancer Vaccines
      • 5.5. Market Analysis, Insights and Forecast – By End-User
        • 5.5.1. Adults
        • 5.5.2. Children
      • 5.6. Market Analysis, Insights and Forecast – By Region
        • 5.6.1. North America
        • 5.6.2. Europe
        • 5.6.3. Asia Pacific
        • 5.6.4. Latin America, Middle East and Africa

      6. North America Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Technology
        • 6.2.1. Dendritic Cells (DC) Cancer Vaccines
        • 6.2.2. Recombinant Cancer Vaccines
        • 6.2.3. Antigen/Adjuvant Cancer Vaccines
        • 6.2.4. Viral Vector & DNA Cancer Vaccines
      • 6.3. Market Analysis, Insights and Forecast – By Indication
        • 6.3.1. Cervical Cancer
        • 6.3.2. Prostate Cancer
        • 6.3.3. Others
      • 6.4. Market Analysis, Insights and Forecast – By Type
        • 6.4.1. Preventive Cancer Vaccines
        • 6.4.2. Therapeutic Cancer Vaccines
      • 6.5. Market Analysis, Insights and Forecast – By End-User
        • 6.5.1. Adults
        • 6.5.2. Children
      • 6.6. Market Analysis, Insights and Forecast – By Country
        • 6.6.1. U.S.
        • 6.6.2. Canada

      7. Europe Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Technology
        • 7.2.1. Dendritic Cells (DC) Cancer Vaccines
        • 7.2.2. Recombinant Cancer Vaccines
        • 7.2.3. Antigen/Adjuvant Cancer Vaccines
        • 7.2.4. Viral Vector & DNA Cancer Vaccines
      • 7.3. Market Analysis, Insights and Forecast – By Indication
        • 7.3.1. Cervical Cancer
        • 7.3.2. Prostate Cancer
        • 7.3.3. Others
      • 7.4. Market Analysis, Insights and Forecast – By Type
        • 7.4.1. Preventive Cancer Vaccines
        • 7.4.2. Therapeutic Cancer Vaccines
      • 7.5. Market Analysis, Insights and Forecast – By End-User
        • 7.5.1. Adults
        • 7.5.2. Children
      • 7.6. Market Analysis, Insights and Forecast – By Country
        • 7.6.1. UK
        • 7.6.2. Germany
        • 7.6.3. France
        • 7.6.4. Italy
        • 7.6.5. Spain
        • 7.6.6. Russia
        • 7.6.7. Rest of Europe

      8. Asia Pacific Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Technology
        • 8.2.1. Dendritic Cells (DC) Cancer Vaccines
        • 8.2.2. Recombinant Cancer Vaccines
        • 8.2.3. Antigen/Adjuvant Cancer Vaccines
        • 8.2.4. Viral Vector & DNA Cancer Vaccines
      • 8.3. Market Analysis, Insights and Forecast – By Indication
        • 8.3.1. Cervical Cancer
        • 8.3.2. Prostate Cancer
        • 8.3.3. Others
      • 8.4. Market Analysis, Insights and Forecast – By Type
        • 8.4.1. Preventive Cancer Vaccines
        • 8.4.2. Therapeutic Cancer Vaccines
      • 8.5. Market Analysis, Insights and Forecast – By End-User
        • 8.5.1. Adults
        • 8.5.2. Children
      • 8.6. Market Analysis, Insights and Forecast – By Country
        • 8.6.1. China
        • 8.6.2. India
        • 8.6.3. Japan
        • 8.6.4. Australia
        • 8.6.5. South East Asia
        • 8.6.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Cancer Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Technology
        • 9.2.1. Dendritic Cells (DC) Cancer Vaccines
        • 9.2.2. Recombinant Cancer Vaccines
        • 9.2.3. Antigen/Adjuvant Cancer Vaccines
        • 9.2.4. Viral Vector & DNA Cancer Vaccines
      • 9.3. Market Analysis, Insights and Forecast – By Indication
        • 9.3.1. Cervical Cancer
        • 9.3.2. Prostate Cancer
        • 9.3.3. Others
      • 9.4. Market Analysis, Insights and Forecast – By Type
        • 9.4.1. Preventive Cancer Vaccines
        • 9.4.2. Therapeutic Cancer Vaccines
      • 9.5. Market Analysis, Insights and Forecast – By End-User
        • 9.5.1. Adults
        • 9.5.2. Children
      • 9.6. Market Analysis, Insights and Forecast – By Country
        • 9.6.1. Brazil
        • 9.6.2. Saudi Arabia
        • 9.6.3. UAE
        • 9.6.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. AstraZeneca plc
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Prima Sanofi
      • 10.6. BioMed
      • 10.7. GlaxoSmithKline
      • 10.8. Merck
      • 10.9. Aduro BioTech
      • 10.10. OncoThyreon
      • 10.11. Oxford BioMedica
      • 10.12. Advaxis Inc.
      • 10.13. Amgen Inc.
      • 10.14. Dynavax Technologies Corporation
      • 10.15. Generex Biotechnology Corporation
      • 10.16. Immunocellular Therapeutics, Ltd
      • 10.17. Sanpower Group Co. Ltd.
      • 10.18. UbiVac
      List of Figures

      Figure 1: Global Cancer Vaccines Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Cancer Vaccines Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Cancer Vaccines Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Cancer Vaccines Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Cancer Vaccines Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Cancer Vaccines Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Cancer Vaccines Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Cancer Vaccines Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Cancer Vaccines Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Cancer Vaccines Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Cancer Vaccines Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Cancer Vaccines Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Cancer Vaccines Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Cancer Vaccines Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Cancer Vaccines Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Cancer Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Cancer Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Cancer Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Cancer Vaccines Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Cancer Vaccines Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Cancer Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Cancer Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Cancer Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Cancer Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Cancer Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934